Recursion's Strategic Acquisition of REV102
Recursion, a prominent clinical stage TechBio company known for its innovative biology decoding strategies, has recently made a significant move in the biopharmaceutical field. The company announced its acquisition of Rallybio’s entire stake in their joint ENPP1 inhibitor program, REV102, along with a backup molecule. This acquisition aims to address hypophosphatasia (HPP), a rare genetic disorder that presents numerous challenges for those affected by it.
The Importance of REV102
REV102 serves as a potential first-in-class oral disease-modifying treatment for HPP patients. With over 7,800 diagnosed individuals in areas like the US and EU5, the need for effective therapies is critical. Currently, many patients have limited access to enzyme replacement therapies (ERTs), which makes developments like REV102 particularly promising. By targeting ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), the program's goal is to restore the balance of inorganic pyrophosphate (PPi), a crucial factor for proper bone mineralization and overall health.
Comments from Leadership
David Hallett, Chief Scientific Officer at Recursion, highlighted the importance of having full ownership of REV102, stating, “This acquisition allows us to expedite the development of a solution for HPP patients who face significant hurdles in accessing effective treatments.” The company recognizes the challenges faced by HPP patients and aims to facilitate their access to disease-modifying therapies.
In line with this sentiment, Stephen Uden, M.D., CEO of Rallybio, expressed gratitude for the partnership and the shared commitment to driving forward with the REV102 program. The collaboration’s foundation has enabled the progression from concept to a candidate poised to meaningfully impact patient lives.
Potential Benefits of REV102
Unlike conventional injectable therapies, REV102 aims to be an accessible oral treatment option. This method not only enhances convenience for patients but may also improve their quality of life significantly. The design and development of REV102 utilized Recursion’s advanced integrated AI and experimental platform, known as the Recursion OS, which optimizes the treatment for potency and safety. As a small molecule, REV102 is expected to have a safer profile, reducing the risk associated with immune responses that can accompany biological ERT treatments.
Development and Future Prospects
The REV102 program marks a pivotal collaboration, with Recursion taking charge of precision design and development. Currently, REV102 is in the IND-enabling phase, with Phase 1 clinical trials slated to begin in the latter half of 2026. Positive early preclinical results show a favorable safety profile in animal models while validating ENPP1 as a promising target.
Financial Arrangements and Strategic Goals
The acquisition arrangement delineates specific financial terms, including an upfront equity payment of $7.5 million and milestone payments as the program advances through clinical phases. Moreover, Rallybio stands to receive royalties on future net sales, establishing a viable financial framework as the partnership progresses.
About Recursion
Recursion (NASDAQ: RXRX) has established itself as a leader in the TechBio sector, focused on decoding biology to enhance drug discovery processes. At the heart of its innovative approach lies the Recursion OS, a robust platform that integrates diverse technologies and continually expands a vast biological and chemical dataset. Through state-of-the-art machine learning algorithms, Recursion distills extensive searchable relationships within biology and chemistry, empowering the next generation of medication advancements.
The company operates at an impressive scale, conducting millions of wet lab experiments weekly while commanding one of the world’s most powerful supercomputers. With headquarters in Salt Lake City and additional offices in prominent locations, Recursion signifies a major force in modern life sciences.
Frequently Asked Questions
What is REV102?
REV102 is a potential first-in-class oral ENPP1 inhibitor designed to treat hypophosphatasia, a rare genetic bone disorder.
What does the acquisition of REV102 mean for Recursion?
This acquisition enables Recursion to take full control of the development of REV102, speeding up its progress toward a potential new treatment for HPP patients.
Why is REV102 considered innovative?
REV102 aims to be an oral, disease-modifying therapy, offering advantages over current injectable treatments, enhancing patient convenience and potentially improving quality of life.
What role does AI play in the development of REV102?
Recursion leverages its integrated AI/experimental platform, the Recursion OS, to optimize the potency and safety of REV102.
What are the next steps for REV102?
REV102 is currently undergoing IND-enabling studies, with the initiation of Phase 1 clinical trials expected to begin in the latter half of 2026.
